格隆汇1月5日丨万东医疗(600055.SH)公布，截至2025年1月5日，公司通过集中竞价交易方式累计回购 股份180.27万股，已回购股份占公司总股本的比例为0.2564%，购买的最高价为17.99元/股、最低价为 15.71元/股，已支付的总金额为2999.28万元（不含交易费用）。 ...

华宝中证医疗ETF（512170）基金经理为胡洁。 1月5日，万东医疗涨5.39%，截至发稿，报16.42元/股，成交1.53亿元，换手率1.35%，总市值115.44亿 元。 资料显示，北京万东医疗科技股份有限公司位于北京市朝阳区酒仙桥东路9号院3号楼，成立日期1997年 5月12日，上市日期1997年5月19日，公司主营业务涉及从事影像类医疗器械的研发、制造、销售及影像 诊断服务。主营业务收入构成为：医疗器械销售业务90.72%，医疗服务及其他5.66%，其他(补 充)3.62%。 从万东医疗十大流通股东角度 数据显示，华宝基金旗下1只基金位居万东医疗十大流通股东。华宝中证医疗ETF（512170）三季度减 持209.86万股，持有股数1191.98万股，占流通股的比例为1.7%。根据测算，今日浮盈赚取约1001.26万 元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模264.04亿。今年以来收益3.89%，同类 排名3822/4189；近一年收益3.89%，同类排名3822/4189；成立以来收益1.8%。 截至发稿，胡洁累计任职时间13年85天，现任基金资产总规模1002 ...

2025年最后一个夜晚，全球X射线影像领域迎来一枚重磅"落子"。 12月31日，行业头部企业锐珂医疗（Carestream Health）发布公告，拟将公司分拆为两大业务板块：一家继续深耕美国本土市场，另一家覆盖美国以外的 全球市场——Carestream International，并由美的集团接手收购。 这一在行业内流传了大半年的消息，终于尘埃落定。锐珂医疗也与它的"前身"柯达公司拿到类似的剧本：被曾经的辉煌时代抛弃，极致收缩之后仍难逃勉 力维持的命运。 自2017年切入医疗产业、2021年以23亿元控股万东医疗起，美的对医疗赛道的投入持续加码。2025年CMEF期间，美的正式宣布成立医疗事业部，将万东 医疗、库卡医疗（手术及康复机器人）、美的生物（医疗冷链）、瑞仕格医疗（医院物流与药房自动化）以及美的楼宇（智慧医院建设与运维）整合至同 一体系之下，并将其确立为集团六大核心业务板块之一。 ▲美的集团旗下六大业务板块（2025年4月发布版本） 01 锐珂分治，美的"摘桃" 根据锐珂医疗官方发布的公告，此次交易并非全盘收购，而是一场经过精密设计的"剥离与重组"。交易完成后，锐珂将被一分为二： 这一边界划分，本 ...

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, becoming the first company to achieve "zero liquid helium" superconducting technology in the A-share market [1][2]. Company Overview - Jianxin Superconducting, established in 2013 and headquartered in Cixi High-tech Industrial Development Zone, focuses on the R&D, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets, permanent magnets, and gradient coils, which account for approximately 50% of the cost of MRI core components [4][7]. - The company has developed a unique all-solid-state conduction cooling technology, achieving a fully helium-free superconducting magnet, with its 1.5T helium-free superconducting magnet already in global commercial application [4][7]. Market Position - As of 2024, Jianxin Superconducting holds a global market share of approximately 4.2%, ranking fifth globally and second among domestic companies, only behind United Imaging Healthcare [7][9]. - The company’s clients for the 1.5T helium-free superconducting magnet include major players such as Wandong Medical, Fujifilm Group, GE Healthcare, and others [7]. Financial Performance - From 2022 to 2025, Jianxin Superconducting's R&D expenses were 20.33 million, 24.42 million, 27.65 million, and 16.75 million yuan respectively [8]. - The company's revenue increased from 359 million yuan in 2022 to 425 million yuan in 2024, with a net profit attributable to shareholders rising from 30.85 million yuan to 50.27 million yuan during the same period [12]. - For the first three quarters of 2025, the company achieved revenue of 393 million yuan, a year-on-year increase of 37.34%, and a net profit of 47.62 million yuan, up 38.54% year-on-year [12]. Industry Trends - The global MRI equipment market is projected to grow from 7.5 billion USD in 2015 to 11.1 billion USD in 2024, with expectations to reach 14.89 billion USD by 2030 [11]. - The cancellation of configuration management for 1.5T and above MRI equipment by the National Health Commission in 2023 is expected to drive the penetration of these devices into the market [11]. - The company is focusing on the development of 3.0T helium-free superconducting magnets, which are anticipated to be a major research direction in the coming years [11].

Core Insights - The core viewpoint of the articles emphasizes the importance of domestic production of MRI equipment, particularly focusing on the self-sufficiency of key components like superconducting magnets and permanent magnets, which are crucial for overcoming industry bottlenecks [1][4]. Company Overview - Jianxin Superconducting has achieved significant technological breakthroughs and large-scale manufacturing in core components such as superconducting magnets and permanent magnets, becoming one of the earliest manufacturers in China to produce high-field superconducting magnets on a large scale and the largest global supplier of MRI equipment permanent magnets [1][4]. - The company has developed a diverse product matrix that includes 1.5T zero-evaporation superconducting magnets, 1.5T liquid helium-free superconducting magnets, and 3.0T zero-evaporation superconducting magnets [4]. Market Position and Strategy - The company aims to make MRI scans more affordable, reducing costs from thousands of yuan to hundreds, and has integrated these services into medical insurance, thereby enhancing access to quality healthcare [1][3]. - Jianxin Superconducting has established deep collaborations with leading manufacturers like Wandong Medical and Shenzhen Anke, ensuring stable supply of 1.5T products and gradually increasing supply of 3.0T products to rural hospitals [6]. Technological Innovation - The company has mastered 13 core technologies with independent intellectual property rights, covering areas such as electromagnetic fields, cryogenics, finite element analysis, structural design, intelligent control, and large-scale manufacturing processes [4]. - Jianxin Superconducting has successfully developed the world's first 1.5T liquid helium-free superconducting magnet, which does not require liquid helium and can automatically recover after quenching, making it suitable for emerging markets with limited maintenance capabilities [6][7]. Global Expansion - The company is actively expanding its overseas market presence, with over 50% of its MRI equipment products sold internationally. It has established local service networks in regions like India and Italy to address the affordability and usability issues in international markets [6][7]. - Jianxin Superconducting's global layout and technological innovations are expected to significantly reduce the overseas delivery and maintenance costs of superconducting magnets, thereby supporting leading manufacturers in promoting their products globally [7]. Long-term Vision - The company emphasizes a long-term commitment to technological innovation and market needs, focusing on core business areas while exploring the feasibility of applying superconducting technology in industrial sectors like wind power and power transmission [9]. - Jianxin Superconducting plans to invest in projects aimed at producing 600 sets of liquid helium-free superconducting magnets annually and upgrading high-field superconducting magnet production, reinforcing its commitment to sustainable growth and innovation in the healthcare sector [9].

"硬科技企业的核心竞争力源于自主研发，健信超导始终坚持'聚焦主业，技术创新'的核心方向。"许建 益表示，基于这一理念，公司对并购重组的态度审慎。短期内，公司将集中资源投入核心技术迭代与产 能扩张，通过内生增长筑牢发展根基。 从具体落地动作来看，健信超导本次募集资金将投向年产600套 无液氦超导磁体项目、年产600套高场强医用超导磁体技改项目，以及新型超导磁体研发项目。 "进入 资本市场后，企业的责任更重、压力更大，但我们绝不会浮躁。"许建益表示，未来健信超导仍将稳扎 稳打，以技术创新为核心驱动力，以市场需求为导向，在医疗健康领域持续赋能民生，在工业领域深挖 超导技术价值，走出一条硬科技企业的高质量发展之路。 "硬科技创业既是技术战，也是持久战。唯有以初心为舵、以坚韧为帆、以格局为岸，才能穿越行业周 期，实现技术报国的梦想。"健信超导董事长许建益表示，"进入资本市场后，企业的责任更重、压力更 大，但我们绝不会浮躁。"未来公司仍将稳扎稳打，以技术创新为核心驱动力，以市场需求为导向，走 出一条硬科技企业的高质量发展之路 在医疗装备国产化浪潮下，MRI（医用磁共振成像）设备核心部 件的自主可控，已成为突破行业瓶颈的关 ...

Core Viewpoint - The company Jianxin Superconductor (688805.SH) has successfully launched on the STAR Market, focusing on the research, production, and sales of core components for medical MRI equipment, which constitute approximately 50% of the cost of MRI devices [1][4]. Group 1: Company Overview - Jianxin Superconductor was established on December 11, 2013, and is recognized as one of the earliest manufacturers in China to scale the production of high-field superconducting magnets [7]. - The company has developed a diverse product matrix, including 1.5T and 3.0T superconducting magnets, and is the largest independent supplier of superconducting magnets globally [7]. - Jianxin Superconductor has established strong partnerships with renowned MRI equipment manufacturers such as Fujifilm, GE Healthcare, and others, facilitating the global promotion of MRI devices [7]. Group 2: Financial Metrics - The IPO price was set at 18.58 CNY per share, with an institutional offering price of 18.89 CNY per share, resulting in a market capitalization of 3.115 billion CNY [4]. - The company’s earnings per share (EPS) is projected with a price-to-earnings (P/E) ratio of 61.97, compared to the industry average of 31.79 [4]. Group 3: Fundraising and Investment Plans - Jianxin Superconductor plans to invest raised funds in several projects, including a 600-unit production line for liquid helium-free superconducting magnets (2.75 billion CNY), a technical upgrade for high-field superconducting magnets (2.60 billion CNY), and the development of new superconducting magnets (2.40 billion CNY) [6]. Group 4: Market Risks - The company faces a high customer concentration risk, with the top five customers accounting for 73.75% to 83.43% of total revenue from 2022 to mid-2025, with Fujifilm being the largest customer [8].

Core Viewpoint - The development and application of liquid helium-free superconducting magnetic resonance technology in China has made significant progress, marking a key step in the country's independent innovation in high-end medical equipment [1] Group 1: Technological Advancements - The "liquid helium-free superconducting magnetic resonance system" project, led by Midea Group's Beijing Wandong Medical Technology Co., Ltd. and Beijing Jishuitan Hospital, has been included in the high-end medical equipment promotion application directory by the Ministry of Industry and Information Technology, the National Health Commission, and the National Medical Products Administration [1] - This technology represents the world's first large-scale application of a 100% liquid helium-free superconducting magnetic resonance product, which has been successfully used in clinical settings across nearly 20 countries in Asia, Europe, and Africa [1] Group 2: Clinical Research and Application - Wandong Medical, in collaboration with Beijing Jishuitan Hospital, is conducting multi-center, large-sample clinical studies to promote continuous optimization and standardized application of the technology across various medical centers in China [2] - The integration of AI-assisted diagnosis, intelligent post-processing workflows, and high-performance hardware platforms enhances diagnostic accuracy and efficiency, making advanced technology more accessible and beneficial for grassroots medical institutions [2]

科创板风险提示 本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风 险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投 资者应充分了解科创板的投资风险及本公司所披露的风险因素，审慎作出 投资决定。 宁波健信超导科技股份有限公司 Ningbo Jansen Superconducting Technologies Co., Ltd. （浙江省慈溪高新技术产业开发区高科大道427号） 首次公开发行股票并在科创板上市 招 股 说 明 书 保荐人（主承销商） 广东省广州市黄埔区中新广州知识城腾飞一街 2 号 618 室 宁波健信超导科技股份有限公司 招股说明书 重要声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股 ...

Core Viewpoint - The article discusses the increasing trend of companies voluntarily abandoning bids for medical equipment procurement projects in China, highlighting the complexities and challenges within the industry, including price competition and regulatory issues [2][12]. Group 1: Bid Abandonment Cases - In 2025, there has been a noticeable increase in cases of companies voluntarily abandoning bids in the medical equipment sector, with notable examples including GE Healthcare abandoning a bid just three days after winning [2][9]. - The case of WanDong Medical, which won a bid for a 1.5T MRI system at a price of 4 million yuan, is particularly striking as the company later chose to abandon the bid after a lengthy and complicated procurement process [4][12]. - The article notes that this year marks the fifth case of a medical equipment manufacturer abandoning a bid, indicating a troubling trend in the industry [9][12]. Group 2: Reasons for Bid Abandonment - Common reasons for voluntary bid abandonment include underestimating production capacity before bidding and discovering that the actual profit margins do not meet expectations after winning the bid [13][14]. - The practice of aggressive price competition, where companies submit low bids to win contracts, often leads to situations where the awarded price is unsustainable for project operation, prompting companies to abandon the bid [13][14]. - High-priced bids may also be abandoned if hospitals express concerns about the pricing, potentially leading to discussions that result in the company voluntarily withdrawing [13][14]. Group 3: Industry Dynamics and Challenges - The medical equipment procurement landscape has shifted towards centralized purchasing, which has significantly reduced costs but has also intensified price competition among manufacturers [20][21]. - The article highlights that the current environment is characterized by high inventory levels and a price war among manufacturers, which has led to declining revenues and profits for leading medical device companies [20][21]. - Regulatory bodies are taking action to address issues of price competition, with recent announcements aimed at maintaining fair market practices and preventing below-cost bidding [21].